An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
PDQ Cancer Information Summaries [Internet].
Bethesda (MD): National Cancer Institute (US); 2002-.
Top results in this bookTable of Contents
Non-Hodgkin's Lymphoma: Diagnosis and Management.
National Guideline Alliance (UK).
London: National Institute for Health and Care Excellence (NICE); 2016 Jul. (NICE Guideline, No. 52.)
Addendum to Haematological Cancers: improving outcomes (update).
National Collaborating Centre for Cancer (UK).
London: National Institute for Health and Care Excellence (NICE); 2016 May.
Brexucabtagene Autoleucel (Tecartus): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Apr.
Calaspargase Pegol (Asparlas): CADTH Reimbursement Recommendation: Indication: As a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 to 21 years [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Jan.
Axicabtagene Ciloleucel (Yescarta): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Feb.
Polatuzumab Vedotin (Polivy): CADTH Reimbursement Recommendation: Indication: Large B-cell lymphoma [Internet].
Glofitamab (Columvi): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with relapsed or refractory DLBCL not otherwise specified, trFL, or PMBCL, who have received 2 or more lines of systemic therapy and are ineligible to receive or cannot receive CAR-T cell therapy or have previously received CAR-T cell therapy [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2024 Feb.
Coeliac Disease: Recognition, Assessment and Management.
London: National Institute for Health and Care Excellence (NICE); 2015 Sep. (NICE Guideline, No. 20.)
Nelarabine (Atriance): CADTH Reimbursement Recommendation: Indication: Nelarabine (Atriance) for addition to front-line multiagent therapy of pediatric, adolescent, and young adult patients (aged 1 year to 30 years at diagnosis) with intermediate- or high-risk T-cell acute lymphoblastic leukemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Oct.
Ibrutinib (Imbruvica): CADTH Reimbursement Recommendation: Indication: Ibrutinib in combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukemia, including those with 17p deletion [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Nov.
CADTH Reimbursement Reviews and Recommendations.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2013-.
Zanubrutinib (Brukinsa): CADTH Reimbursement Recommendation: Indication: For the treatment of adult patients with chronic lymphocytic leukemia [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 Sep.
Neutropenic Sepsis: Prevention and Management of Neutropenic Sepsis in Cancer Patients.
London: National Institute for Health and Clinical Excellence (NICE); 2012 Sep. (NICE Clinical Guidelines, No. 151.)
Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [Internet].
Bethesda (MD): National Institutes of Health (US); 2021 Apr 21-2024 Feb 29.
Crisantaspase Recombinant (Rylaze): CADTH Reimbursement Recommendation: Indication: As a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients 1 year or older who have developed hypersensitivity to E. coli-derived asparaginase [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2023 May.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on